Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In GD_M4, a synthetic RBS was introduced to reduce translation of gIII, thereby increasing the stringency of selection for proteases that produce higher RNAP output (Extended Data Fig
Diagnostics 13 , 2158 (2023)
Fe(III)-Shikonin supramolecular nanomedicine for combined therapy of tumor via ferroptosis and necroptosis
Among late phase trials, Lixisenatide (n = 5) showed the lowest eligibility rates (5.8% Non-Asian US) due to strict HbA1c requirements (7.510%), while Dulaglutide (n = 7) showed the highest variability (SD = 46.2%)
US$ 22.59
US$ 28.42
US$ 26.47
US$ 28.56
US$ 29.74
US$ 20.24
